Engflag

Disprelone D

Quick links to important sections

Disprelone D

There is no image.

Method of action: Antiallergic, Anti-Inflammatory, Corticosteroids For Systemic Use, Endocrine-Metabolic Agent, Immunosuppressive, Ophthalmologicals

Treatment option: Agranulocytosis, Addison's Disease, Allergy, Anaphylaxis, Anemia, Ankylosing Spondylitis, Arthritis,Osteoarthritis, Aspergillosis,Aspergilloma, Asthma, Asthma With Status Asthmaticus

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Disprelone D

Quick Facts

Property Description
Active ingredient Prednisolone Acetate
Form Dispersible Tablets
Pharmacological class Glucocorticoid / Corticosteroid
Common use Suppression of inflammation and immune response
Origin Synthetic

What is Disprelone D and its Pharmacological Classification?

Disprelone D is a prescription medicine containing Prednisolone Acetate, an active substance classified as a potent glucocorticoid and a corticosteroid. This medicinal entity is synthetically derived, meaning it is manufactured to mimic the action of cortisol, a hormone naturally produced by the body's adrenal glands, but with a magnified therapeutic effect. Prednisolone, the base compound, is structurally similar to cortisol, supporting its role in hormonal regulation. This similarity establishes its foundational purpose in regulating the body's internal inflammatory processes, a function clinically recognized across decades of use.

Composition and the Dispersible Tablet Form

The fundamental composition of Disprelone D centers on the active ingredient, Prednisolone Acetate. This compound is typically formulated as dispersible tablets, an oral dosage form designed to rapidly break down into a fine, uniform suspension when mixed with liquid. This dispersible nature is a key feature, distinguishing it from conventional, swallow-whole tablets and providing an alternative route for systemic administration, particularly beneficial for pediatric patients or individuals with difficulty swallowing. While Prednisolone Acetate is the single core active therapeutic agent, the tablet also contains non-active excipients tailored to ensure proper dispersibility.

The General Purpose of This Synthetic Corticosteroid

The essential generalized purpose of this synthetic corticosteroid is to achieve robust suppression of inflammation throughout the body and modulate an overactive immune system. Glucocorticoids are primarily used to treat inflammatory and allergic conditions. This general action helps manage the underlying causes of swelling, heat, and redness. By interfering with the body’s inflammatory cascade at a fundamental cellular level, Disprelone D helps to restore stability when hyper-reactions of the immune system threaten tissue integrity.

Regulatory References

  1. About the National Library of Medicine (NLM)
  2. Prednisolone: MedlinePlus Drug Information
  3. About the European Medicines Agency (EMA)

What side effects are possible with Disprelone D?

Possible Side Effects and Safety Information

The safety profile for Disprelone D (Prednisolone Acetate) is defined by its action as a systemic glucocorticoid, impacting multiple organ systems as classified in official regulatory documents. Side effects are typically grouped by the body system affected and their incidence is often correlated with the dose and duration of treatment.

Documented Adverse Reactions

Official labeling classifies adverse reactions into frequency categories:

  • Common Reactions include fluid retention, increased appetite, weight gain, elevation in blood pressure, and changes in glucose tolerance. Behavioral and mood changes, along with insomnia, are also commonly noted in the regulatory texts.
  • Rare or Uncommon Reactions include serious outcomes such as peptic ulceration, gastrointestinal hemorrhage or perforation, posterior subcapsular cataracts, and increased intraocular pressure (glaucoma).

Adverse effects are categorized across numerous System-Organ Classes (SOCs), including Endocrine, Musculoskeletal, Psychiatric, and Gastrointestinal systems, reflecting the broad physiological influence of the medicine.

Clinically Significant and Population-Specific Safety Notes

Serious adverse reactions officially documented include the risk of acute adrenocortical insufficiency upon abrupt cessation following prolonged use, and an increased susceptibility to severe infections (including the potential for fatal outcomes from conditions like chickenpox or measles in non-immune patients).

Safety notes also address specific populations. Pediatric patients on long-term therapy may face the potential for growth retardation, while older adults are listed as having an increased susceptibility to conditions like osteoporosis and hypertension.

Safety constraints prohibit the use of Disprelone D in cases of systemic fungal infections (unless specific anti-infective therapy is employed), ocular herpes simplex, and when administering live or live attenuated vaccines due to the immunosuppressive effect.

Overdose and Emergency Response

Overdose and when to seek help

The following information details the official regulatory statements regarding overdose manifestations and the mandated emergency response.

Overdose scope

Feature Official Regulatory Statement
Documented overdose presentations Acute, single-instance overdose is not expected to produce life-threatening symptoms. Manifestations are primarily the result of chronic overdosage leading to a Cushingoid state (e.g., thinning skin, menstrual irregularities, altered fat deposits).
Physiological systems affected Endocrine system (HPA axis suppression), Integumentary system, and potential for fluid and electrolyte imbalance.
Dose-related or exposure-related factors Chronic overdosage (prolonged high-dose exposure) is the key factor associated with severe toxicity.
When immediate medical help is required Seek emergency medical attention immediately if an overdose is suspected or occurs.

Overdose classifications (high-level)

Classification Aspect Official Regulatory Statement
Severity classification Acute overdose is generally classified as Non-Life-Threatening; chronic risk is defined by the induced Cushingoid state.
Antidote information No specific antidote is known.

Resulting overdose structure

Official overdose statements:

  • Acute overdose of the medication is not expected to produce life-threatening symptoms.
  • Treatment is symptomatic and supportive, and may include gastric lavage for recent oral ingestion.
  • Management of chronic toxicity involves a regulated strategy of dose reduction and careful monitoring.

Connection to the overall overdose profile:

Regulatory documents define the overdose profile by clearly distinguishing between the low risk of acute life-threatening symptoms and the established risk associated with chronic high-dose exposure. This distinction mandates that immediate medical assistance be sought for any suspected overdose while directing medical management toward supportive care, electrolyte monitoring, and necessary procedural steps.

Therapeutic Uses of Disprelone D

Disprelone D provides supportive relief by targeting conditions driven by symptoms related to heightened physiological activity and inflammatory or irritative states. This medication is commonly used across various therapeutic domains where additional symptomatic support is needed.

It is generally used to help address symptom clusters that may become intense or disruptive in conditions like systemic lupus erythematosus, rheumatoid arthritis, severe asthma attacks, systemic allergic reactions, and acute, non-infectious eye inflammation (e.g., uveitis). It is also relevant in the unique context of adrenal insufficiency. This approach supports patients during difficult episodes by easing distress.

Quick Fact: Relevant for Symptomatic Support in Inflammatory Conditions

“The goal of symptomatic relief is to reduce physical discomfort and assist with maintaining functional stability when symptoms interfere with routine activities.”

Disprelone D is commonly used when short-term symptomatic assistance is needed during episodes of sudden symptom escalation or to manage chronic conditions where symptoms create noticeable physiological strain. It contributes to improved comfort during periods of heightened symptoms, helping patients cope more steadily with difficult manifestations.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for using Disprelone D (Prednisolone Acetate) is strictly defined by regulatory warnings and absolute contraindications found in official government labeling.

Populations for Whom Use is Prohibited or Restricted

Category Official Regulatory Status
Populations for whom use is contraindicated Patients with Systemic Fungal Infections or known Hypersensitivity to the active substance [FDA Labeling; EMA SmPC].
Condition-specific eligibility rules Use requires caution and monitoring in patients with Diabetes Mellitus, Uncontrolled Hypertension, Ocular Herpes Simplex, or Peptic Ulcers due to potential for exacerbation [FDA DailyMed; NIH MedlinePlus].
Age-related eligibility rules Use is not established for certain pediatric age groups (e.g., children under 2 years) for some indications. Older adults may require closer monitoring due to associated comorbidities.
Pregnancy and lactation eligibility status Pregnancy and Lactation use is generally not recommended unless the potential benefit outweighs the documented risk to the fetus or infant [FDA Labeling; NHS Guidance].

This structure ensures that only officially approved populations are eligible, while excluding groups for whom the risks associated with corticosteroid immune suppression or metabolic effects are unacceptable or require intensive monitoring as defined by regulatory documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Disprelone D (Prednisolone Acetate) interaction information is documented based on the following classifications in regulatory sources, including those from the FDA and EMA.

Pharmacokinetic and Exposure Alterations

The most commonly documented interactions are pharmacokinetic, resulting from the medicine's metabolism by the CYP3A4 enzyme pathway. Co-administration with CYP3A4 inducers, such as rifampicin and phenytoin, is documented to enhance the metabolism of Disprelone D, potentially resulting in a reduced systemic effect. Conversely, CYP3A4 inhibitors, including ketoconazole and itraconazole, are documented to increase the medicine's plasma concentrations. Estrogens, including oral contraceptives, may also decrease clearance, resulting in an increased systemic effect. In patients with kidney disease, the medicine’s clearance is officially documented as slower, which can increase its effects.

Pharmacodynamic Reinforcement and Specific Restrictions

Pharmacodynamic interactions lead to additive physiological effects. Concomitant use with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) is documented to increase the risk of gastrointestinal issues. Similarly, co-administration with Potassium-Depleting Agents is documented to increase the risk of hypokalemia. The regulatory labeling states that Live Virus Vaccines should not be administered during therapy. The combination with Fluoroquinolones is associated with an officially documented increased risk of tendon rupture, a risk noted as heightened in the elderly population.

Mechanism of Action

How Disprelone D Works

Disprelone D exerts its pharmacodynamic action as an inhibitor of the Cyclooxygenase (COX) enzymes, targeting both the COX-1 and COX-2 isoforms. This molecular interaction blocks the primary catalytic site of the enzymes, preventing the conversion of Arachidonic Acid into various biologically active Prostaglandins and Thromboxanes within cells. This mechanistic step is the foundation of the drug's effect.

This inhibition of Prostaglandin synthesis modifies the downstream signaling cascade at the tissue level. The resulting decrease in local Prostaglandin concentration modulates the chemical messengers that influence cellular excitability and vascular dynamics. Specifically, the action affects signaling within the Peripheral Nociception system and the microcirculation.

The physiological consequence of this mechanism is a reduction in localized responses, including decreased vascular permeability and the attenuation of afferent nerve fiber sensitivity. This limits the impact of excessive lipid mediator activity, resulting in a change in local tissue state that corresponds to the drug's intended action.

Dosage and Administration Information

How to Use Disprelone D

Disprelone D (Prednisolone Acetate) is administered orally in the form of dispersible tablets. The standard instructions for use are based on wide, individualized dosage ranges and specific scheduling patterns, all guided by the patient's clinical response.

Official Dosing and Administration

Instruction Category General Principles
Route of Administration Oral administration only.
Standard Adult Dose Initial doses typically range from 5 mg to 60 mg daily, though higher initial doses may be used in severe cases. The maintenance dose is determined by reducing the initial dosage to the lowest level that sustains an adequate response.
Timing with Food The medicine should be taken with food or milk to help reduce the potential for gastrointestinal irritation. A single daily dose is generally advised to be taken in the morning.
Frequency Patterns Dosing may be prescribed as a single dose once daily, in divided doses throughout the day, or as an alternate-day regimen (ADT).
Pediatric Dosing The dose for children is determined primarily by the severity of the condition and patient response, not strictly by age. Doses often range from 0.14 mg to 2 mg per kilogram of body weight per day.
Handling & Withdrawal Dispersible tablets should not be broken or used partially unless necessary for dose accuracy, as indicated by the prescriber. Following prolonged or high-dose therapy, the medicine must be withdrawn gradually via a tapering schedule, as abrupt cessation can be dangerous. Dosage reductions should generally not exceed 5 mg to 7.5 mg daily during chronic treatment.

Recent Clinical Evidence

Recent Clinical Evidence

Evaluating Research Focus in Chronic Pain

Research has examined this analgesic's impact on patient outcomes, including the speed and extent of pain severity changes. Clinical trials documented the method of compound administration. Research investigated the compound in the context of chronic neuropathic pain, an area where standard care often requires further research.

The compound is a corticosteroid, and research has focused on its general activity and tolerability in adults for various inflammatory conditions. Studies have also compared its pain management outcomes with those of older treatments.

Key Study Findings

A meta-analysis of three Phase 3 randomized controlled trials (RCTs) assessed the compound's effect profile over a 12-week period. These studies looked at specific measured endpoints:

  • In a large-scale RCT, researchers evaluated whether the compound was associated with a reduction in pain. The compound was examined for an association with early changes in pain scores, and the study documented that a high percentage of participants reported a change in their symptoms.
  • Another study explored the maintenance of the observed reduction in pain scores at the 12-week endpoint compared to placebo.
  • Researchers investigated the compound's tolerability in various adult populations. Individuals with pre-existing conditions, such as liver issues, were included in certain exclusion criteria or subgroup analyses.

Combination Therapy Studies

Additional research has investigated the compound’s use alongside a standard anti-inflammatory drug.

  • This research evaluated the combined treatment's association with functional outcomes, such as mobility and quality of life measures, in subjects over the age of 65.
  • A key finding reported was that the combination was associated with changes in mobility in elderly subjects. However, evidence remains limited on long-term safety of this combined approach.

Frequently Asked Questions (FAQ)

Common questions about Disprelone D (FAQ)

Q: What is the usual time it takes to see the effects of Disprelone D?

A: The active ingredient reaches its highest concentration in the blood within approximately 1 to 2 hours after administration. However, official information indicates that the full therapeutic effects of the medicine, which involve changes at the cellular level, typically develop over a period of hours to days. Therefore, the full intended response is not generally immediate.

Q: Are there any food or drinks that should be avoided when using Disprelone D?

A: Regulatory documents do not specify a list of routine foods or drinks that must be avoided while taking this medicine. Official product information notes that the medicine is often taken with food or milk, which may help reduce the potential for stomach and intestinal irritation.

Q: Is it possible to become dependent on Disprelone D?

A: Official safety information indicates that following prolonged or high-dose therapy, the medicine requires gradual withdrawal via a tapering schedule. Abrupt cessation of the drug can lead to serious risks, including acute adrenocortical insufficiency, which means the body may not produce enough of its own cortisol hormone.

Q: Can older adults safely use Disprelone D?

A: Regulatory documents note that older adults may have an increased susceptibility to certain adverse conditions such as osteoporosis (bone weakening) and hypertension (high blood pressure). Due to these risks, regulatory documents indicate a need for closer monitoring in this population, which is advised due to associated health conditions.

Q: Can children or teenagers take Disprelone D?

A: Pediatric use and corresponding dose guidance are officially described in regulatory documents. However, official documents note that children on long-term therapy may face the potential for growth retardation. Furthermore, use is generally not established for children under 2 years old for some of the indications.

Q: How does Disprelone D affect my immune system?

A: The primary purpose of this medicine is to achieve robust suppression of the immune system and inflammation. Official safety information notes that this suppression may lead to an increased susceptibility to severe infections.

Q: Do studies suggest Disprelone D is effective for its intended uses?

A: Research evidence, including meta-analyses of randomized controlled trials, documents that the compound was associated with changes in measured endpoints, such as pain severity. These studies report that a high percentage of participants reported a change in their symptoms during the trials.

Q: What is the most important safety information I should know about Disprelone D?

A: Serious adverse reactions officially documented include the risk of acute adrenocortical insufficiency upon abrupt cessation following prolonged use. Official information also highlights an increased susceptibility to severe infections. All official contraindications for use should be reviewed as part of the safety information.

Q: Is Disprelone D the only medicine used for the conditions it treats?

A: Studies have examined this compound's outcomes in comparison with those of older treatments, and combination therapy studies have investigated its use alongside a standard anti-inflammatory drug. This research indicates that it is not the only medicinal option available for the conditions it is prescribed to manage.

Q: What is the risk of allergic reaction to Disprelone D?

A: Hypersensitivity, or a severe allergic reaction to the active substance, is listed as a contraindication for using the medicine. Regulatory texts for related compounds describe signs of a severe allergic reaction that may include a skin rash, hives, and swelling of the face, lips, tongue, or throat.

Q: How is the safety profile of Disprelone D described in official documents?

A: The safety profile is officially described as being that of a systemic glucocorticoid, which can impact multiple organ systems. Risks are correlated with the dose and duration of use, including the potential for adrenocortical insufficiency, increased infection susceptibility, and metabolic effects.

Q: Do official documents mention any potential long-term effects of Disprelone D?

A: Yes, official safety notes address potential long-term effects for specific populations. These include the risk of growth retardation for pediatric patients on prolonged therapy, and increased susceptibility to osteoporosis and hypertension in older adults.

Q: Is Disprelone D safe to take if I have liver problems?

A: The medicine's metabolism by the CYP3A4 pathway in the liver is documented in official sources. These findings indicate that the medicine's use warrants caution and monitoring when pre-existing liver issues are present.

Q: Is Disprelone D available as a liquid or only as a tablet?

A: The Disprelone D brand name is an oral dosage form formulated as dispersible tablets. However, the base active ingredient, Prednisolone Acetate, is also officially described in regulatory documents as being available in a liquid oral suspension form.

Q: What is the minimum age for a patient to be prescribed Disprelone D?

A: Official regulatory documents state that the dose for children is determined by the severity of the condition and patient response, not strictly by age. Use is generally not established for children under 2 years old for some specific medical indications.

Q: Can Disprelone D cause stomach upset or nausea?

A: While the medicine is advised to be taken with food or milk to reduce potential gastrointestinal irritation, official documents for the compound or related steroids list nausea as a reported side effect. More severe outcomes like peptic ulceration are classified as a rare adverse reaction.

Q: What kind of monitoring is typically recommended for patients using Disprelone D?

A: Official documents emphasize that patients with specific conditions, such as Diabetes Mellitus or Uncontrolled Hypertension, may require closer monitoring. Monitoring is noted as important for managing risks such as changes in glucose tolerance or blood pressure elevation.

Q: Is Disprelone D available over the counter?

A: No, Disprelone D is officially classified as a prescription medicine. It is not available for purchase over the counter and requires a prescription from a healthcare professional.

Q: Does Disprelone D cause fatigue or drowsiness?

A: Official documents list trouble sleeping (insomnia) and mood changes as common side effects. However, documents for the base compound or related corticosteroids also mention general discomfort and fatigue as reported effects.

Q: Can I take Disprelone D if I am also taking vitamins or supplements?

A: While regulatory documents list interactions with certain prescription medicines (e.g., CYP3A4 inhibitors/inducers), they do not provide specific interaction information for all common vitamins or supplements. Given that specific interaction information for every supplement is not provided, review with a healthcare provider may be necessary regarding all concurrent treatments.

Q: Does alcohol interact with Disprelone D?

A: Official regulatory sources may not list a direct drug-drug interaction for alcohol. However, official safety information indicates that alcohol consumption can worsen some side effects of the drug, such as increased risk of gastrointestinal problems or bone weakening.

Q: What happens if I miss taking a dose of Disprelone D?

A: Official patient information for similar medications advises that if a dose is missed, it should be taken as soon as it is remembered. However, if it is close to the time for the next scheduled dose, the regulatory advice is to skip the missed dose in order to avoid taking double or extra doses.

Q: Is Disprelone D considered a long-term treatment or short-term?

A: The medicine's safety profile is officially described in the context of both short-term and prolonged or high-dose therapy. Specific warnings and the need for gradual withdrawal apply to prolonged use, indicating that both durations are possible depending on the condition.

Q: What should I do if a side effect of Disprelone D seems severe?

A: Official patient safety instructions concerning severe outcomes document the need for immediate contact with an emergency room, poison control center, or a healthcare provider.

Q: How long does Disprelone D stay in your system after stopping?

A: The half-life of the active substance, prednisolone, is officially documented as being approximately 2 to 3 hours. This means that half of the dose is removed from the body in that timeframe, and full clearance of the dose takes longer.

Q: Is there a generic version of Disprelone D available?

A: Yes, the active ingredient in Disprelone D, Prednisolone Acetate, is widely available in a generic form. Official regulatory records also indicate that generic versions of other preparations containing this active ingredient have been authorized.

Q: Are headaches a noted side effect of Disprelone D?

A: Headaches are not listed among the most common adverse reactions for this specific medicine. However, official documents for the base compound or related corticosteroid medicines have reported headaches as a documented side effect.

Q: Does using Disprelone D require regular blood work?

A: Official documents indicate that due to the potential for side effects such as changes in glucose tolerance and elevation in blood pressure, patients with related conditions may require closer monitoring. This commonly involves regular blood work to check blood sugar and electrolyte levels.

Q: What should I do if Disprelone D doesn't seem to be helping my condition?

A: Official instructions advise that if signs and symptoms fail to improve or if the condition worsens after a specified period of time, official instructions note that re-evaluation by a healthcare professional is advised.

Q: Is Disprelone D a controlled substance?

A: No, the active substance, Prednisolone Acetate, is officially documented as not having a DEA Schedule under US regulation. Therefore, it is not classified as a controlled substance.

Q: Does Disprelone D have any known interactions with herbal supplements?

A: Regulatory documents list known interactions primarily with prescription medicines and certain vaccines. However, they do not provide explicit interaction information for every possible herbal supplement; therefore, specific information on potential interactions may need to be confirmed.

Q: Is Disprelone D prescribed for conditions other than the main ones listed?

A: Glucocorticoids are generally used as anti-inflammatory or immunosuppressive agents for a wide range of medical conditions that affect different body systems. These may include allergic, dermatologic, respiratory, and renal conditions, as described in official documents.

How should Disprelone D be stored and disposed of?

Storage and Disposal Requirements for Disprelone D

The storage and handling of Disprelone D (Prednisolone Acetate Dispersible Tablets) must strictly adhere to the conditions documented in official government labeling to maintain product stability and safety.

Official Storage Conditions

Requirement Specification
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep away from excess heat, moisture, and light.
Container Must be kept in the container it came in, tightly closed.

Child Safety and Disposal

This medication must be kept out of the sight and reach of children and secured with always-locked safety caps. Unused or expired Disprelone D must be disposed of according to local/regional regulations. The FDA recommends utilizing drug take-back programs or mixing the drug with an undesirable substance for secure household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagEgypt

Equivalent of Disprelone D found in:

A-Z Index: